Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate AC Immune SA before investing.

In this article, we go over a few key elements for understanding AC Immune SA’s stock price such as:

• AC Immune SA’s current stock price and volume
• Why AC Immune SA’s stock price changed recently
• Upgrades and downgrades for ACIU from analysts
• ACIU’s stock price momentum as measured by its relative strength

About AC Immune SA (ACIU)

Before we jump into AC Immune SA’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson’s disease; and ACI-35.030, designs to stimulate a patient’s immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Want to learn more about AC Immune SA’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about AC Immune SA.

AC Immune SA’s Stock Price as of Market Close

As of December 22, 2025, 3:59 PM, CST, AC Immune SA’s stock price was $3.175.

AC Immune SA is up 4.79% from its previous closing price of $3.030.

During the last market session, AC Immune SA’s stock traded between $3.030 and $3.200. Currently, there are approximately 126.54 million shares outstanding for AC Immune SA.

AC Immune SA’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

AC Immune SA Stock Price History

AC Immune SA’s (ACIU) price is currently up 6.19% so far this month.

During the month of December, AC Immune SA’s stock price has reached a high of $3.800 and a low of $2.540.

Over the last year, AC Immune SA has hit prices as high as $4.000 and as low as $1.430. Year to date, AC Immune SA’s stock is up 17.59%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused AC Immune SA Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 19, 2025, there were 0 analysts who downgraded AC Immune SA’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate AC Immune SA’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on AC Immune SA’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

AC Immune SA’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about AC Immune SA (ACIU) by visiting AAII Stock Evaluator.

Relative Price Strength of AC Immune SA

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 19, 2025, AC Immune SA has a weighted four-quarter relative price strength of 3.17%, which translates to a Momentum Score of 66 and is considered to be Strong.

Want to learn more about how AC Immune SA is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

AC Immune SA Stock Price: Bottom Line

As of December 22, 2025, AC Immune SA’s stock price is $3.175, which is up 4.79% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like AC Immune SA stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.